WASHINGTON: Most side effects after the third dose of the covid vaccine are mild or moderate, and more often than not after two shots, a U.S. study found Tuesday in a search that was expected but Despite this, assurances were given.
The Centers for Disease Control and Prevention (CDC) report came from more than 22,000 people who signed up for the Vaccine Safety smartphone app and who took a booster shot between August 12 and September 19. Got it.
During this time, the third dose was given to people who were immune, but not to the general population.
“The frequency and type of side effects were similar to those seen after the second vaccine dose, and were mostly mild or moderate and short-lived,” CDC Director Rochelle Valensky said in a press briefing.
The most commonly reported side effects include injection site pain (71% of study participants), fatigue (56%), and headache (43%).
Some 28% reported being unable to perform normal daily activities, usually the next day.
About 2% of the participants received medical care and 0.1% or 13 people were hospitalized.
Approximately 21 subsets of 21,700 who received the same mRNA vaccine (Moderna or Pfizer) for their three doses were further analyzed.
In non-modern recipients, local reactions – such as arm pain – were reported to be slightly more common after the third dose than the second.
Systemic reactions – that is, those that occurred outside the injection site – were slightly lower after the third dose than with the second.
The same pattern occurred for Pfizer, and in both cases, the first shots resulted in significantly less frequent side effects, especially with Nizami, two and three shots.
Last week, U.S. health agencies approved the Pfizer booster dose for people over the age of 65, 18-64 year olds with a basic medical condition such as diabetes or obesity, and those who live and work specifically because of their work or where they live. Are infected with this virus. .
The CDC warned that its report had some limitations.
These include the fact that signing up for a smartphone app called “VSafe” was voluntary and participants were more white than the national population.
During the study period, some non-immune compromises may have received a booster beyond the recommendations because they were concerned about the elimination of the exemption, and therefore the results are reliably available only to those with immune compromises. Cannot connect to